ライフサイエンスコーパス: bispecific antibody

1 fficiently in the presence of the CD70-fiber bispecific antibody.

2 ed in the same cell to assemble a functional bispecific antibody.

3 Using this approach, we produce 28 unique bispecific antibodies.

4 d in the same cell to generate heterodimeric bispecific antibodies.

5 ction provides a novel synthetic approach to bispecific antibodies.

6 small-scale generation of human full-length bispecific antibodies.

7 armacophores to generate optimized or unique bispecific antibodies.

8 ltaneous targeting of two tumor targets with bispecific antibodies.

9 and improved sources of clinically relevant bispecific antibodies.

10 ery with possible functional implications in bispecific antibodies.

11 tent antibodies and explore the potential of bispecific antibodies.

12 One bispecific antibody, 10E8V2.0/iMab, neutralized 118 HIV-

13 We produced a bispecific antibody (3F12) which binds influenza virus M

14 With the recent clinical success of bispecific antibodies, a strategy to rapidly synthesize

15 nd, we produced a recombinant human IgG-like bispecific antibody, a Di-diabody, using the variable re

16 NA to reduce antithrombin expression and the bispecific antibody ACE910/emicizumab.

17 Synergistic bispecific antibodies against HIV exhibit extraordinary

18 We have shown that bispecific antibodies against TfR and beta-secretase (BA

19 We report a bispecific antibody against B cell maturation antigen (B

20 A bispecific antibody against the receptor tyrosine kinase

21 Here, we describe the synthesis of a novel bispecific antibody, alphaCLL1-alphaCD3, using the genet

22 mune activation of cytotoxic effector cells, bispecific antibodies and antibodies linked to superanti

23 Bispecific antibodies and antibody fragments are a new c

24 rogeneous biopharmaceutical products such as bispecific antibodies and antibody mixtures.

25 ntibody-drug conjugates, conjugate vaccines, bispecific antibodies and cell therapy.

26 These results support this new approach to bispecific antibodies and offer a potential new strategy

27 successfully redirected to tumor cells using bispecific antibodies and offer a promising strategy for

28 Bispecific antibodies and recombinant proteins are also

29 rved following administration of natural and bispecific antibodies and, more recently, following adop

30 ased on a glycoprotein A33 (GPA33)-targeting bispecific antibody and a small-molecule radioactive hap

31 Bispecific antibody and antibody-like molecules are of w

32 Psl, and susceptibility to the anti-PcrV/Psl bispecific antibody and clinical candidate MEDI3902.

33 undergo in vivo Fab arm exchange leading to bispecific antibody and off-target effects.

34 Fc containing therapeutics (e.g. antibodies, bispecific antibodies, and Fc fusions) requiring lack of

35 , leading to the formation of monovalent but bispecific antibodies, and it interacts poorly with Fcga

36 position of the blood-brain barrier-crossing bispecific antibody antagonist of metabotropic glutamate

37 ess in research on intracellular antibodies, bispecific antibodies, antibody-fusion molecules, and an

38 otein-coupled receptors using a BBB-crossing bispecific antibody approach and emerging principles tha

39 Bispecific antibodies are considered attractive bio-ther

40 the generation of large numbers of different bispecific antibodies are presented.

41 These results suggest that IgG-based bispecific antibodies are promising candidates for the p

42 However, FVIII and the bispecific antibody are fundamentally different proteins

43 Chimeric proteins, including bispecific antibodies, are biological tools with therape

44 ignaling pathways were evaluated during EGFR bispecific antibody armed ATC (aATC)-mediated killing of

45 The development of bispecific antibodies as therapeutic agents for human di

46 payloads such as other antibodies to create bispecific antibodies as well as organic and non-organic

47 nity Re-Targeting (DART) proteins, which are bispecific, antibody-based molecules that can bind 2 dis

48 Comparison with a single-chain, bispecific antibody bearing identical CD19 and CD3 antib

49 Chemically programmed bispecific antibodies (biAbs) endow target cell-binding

50 Bispecific antibodies (biAbs) that mediate cytotoxicity

51 o 20-fold more potently than a CS1-targeting bispecific antibody (BiFab-CS1) developed in an analogou

52 this approach to the development of chimeric bispecific antibody binding site (chi BABS) proteins.

53 e used antibody engineering to develop novel bispecific antibodies (Bis-mAbs) that are cross-reactive

54 pecificities can dissociate and recombine in bispecific antibodies both in vitro and in vivo.

55 ltaneous engagement of two distinct targets, bispecific antibodies broaden the potential utility of a

56 We previously described a highly flexible bispecific antibody (bs-mAb) pretargeting procedure usin

57 ied using PrA-MS and are presented here: (a) bispecific antibodies (bsAb) and (b) glycan engineered a

58 Methods to rapidly generate high quality bispecific antibodies (BsAb) having normal half-lives ar

59 nical studies to date have demonstrated that bispecific antibodies (BsAb) may have potentially signif

60 The use of bispecific antibodies (BsAb) provides integration of the

61 T cell-recruiting bispecific antibodies (bsAb) show promise in hematologic

62 ted and produced two fully human recombinant bispecific antibodies (BsAb) that target both EGFR and I

63 ectively targeted against malignant B cells, bispecific antibodies (BsAb) were constructed from two a

64 s such as antibody-drug conjugates (ADC) and bispecific antibodies (bsAb), are the fastest growing cl

65 d DNL to generate a novel class of trivalent bispecific antibodies (bsAb), each comprising an anti-CD

66 for the generation of therapeutic human IgG1 bispecific antibodies (bsAb).

67 ived macrophages mediated by MAb DF3 and its bispecific antibody (BsAb) DF3xH22 with the second epito

68 In order to target alpha v integrins, a bispecific antibody (bsAb) that comprised a monoclonal A

69 inical evaluation of a recombinant AC133xCD3 bispecific antibody (bsAb) that redirects human polyclon

70 Among these, a Her2 x CD3 bispecific antibody (BsAb) was constructed by inserting

71 These deficiencies were overcome by using a bispecific antibody (bsAb) with specificities for human

72 Bispecific antibodies (bsAbs) and antibody-drug conjugat

73 Bispecific antibodies (bsAbs) are Abs composed of two di

74 Bispecific antibodies (bsAbs) are of significant importa

75 Bispecific antibodies (bsAbs) are one of the most versat

76 Bispecific antibodies (BsAbs) are regarded as promising

77 Bispecific antibodies (bsAbs) combine the antigen specif

78 a pair of humanized hexavalent anti-CD20/22 bispecific antibodies (bsAbs) derived from veltuzumab (v

79 We prepared bispecific antibodies (bsAbs) for disease-specific targe

80 Many methods have been developed to produce bispecific antibodies (BsAbs) for industrial application

81 cacy of engaging multiple drug targets using bispecific antibodies (BsAbs) is affected by the relativ

82 g T cells to hematological malignancies with bispecific antibodies (BsAbs) is an attractive strategy.

83 Producing pure and well behaved bispecific antibodies (bsAbs) on a large scale for precl

84 Bispecific antibodies (BsAbs) target multiple epitopes o

85 Bispecific antibodies (bsAbs) that lack the immunoglobul

86 The promise of bispecific antibodies (bsAbs) to yield more effective th

87 Four different formats of bispecific antibodies (bsAbs) were generated that consis

88 onal mouse anti-TnI IgG mAb 265, (2) TnI and bispecific antibodies (BsAbs) which on one end recognize

89 This results in functionally monovalent, bispecific antibodies (bsAbs) with unknown specificity a

90 Bispecific antibodies (bscAbs), particularly those of th

91 chimeric anticarcinoembryonic antigen (CEA) bispecific antibody (BsMAb) and peptides labeled with (1

92 ing method using a new recombinant anti-CD20 bispecific antibody (bsMAb) followed by (90)Y-1,4,7,10-t

93 A flexible bispecific antibody (bsMAb) multistep, pretargeting syst

94 Bispecific antibodies, but not parent mAbs, neutralized

95 We have produced novel bispecific antibodies by fusing the DNA encoding a singl

96 rm of generating bispecific IgG antibodies, "Bispecific Antibody by Protein Trans-splicing (BAPTS)".

97 e, we review the principle of a new class of bispecific antibodies called BiTE (for "bispecific T-cel

98 We show that IgG4 bispecific antibodies can be generated in large quantiti

99 Bispecific antibodies can be used to redirect cytotoxic

100 us, Ad) vectors targeted to CD40 by means of bispecific antibodies can enhance gene transfer to murin

101 These results indicate that the CD70-fiber bispecific antibody can enhance rAd infection of CD70-po

102 he two parental antibodies and that a single bispecific antibody can neutralize 97% of viral strains

103 Bispecific antibodies capable of redirecting the lytic p

104 Bispecific antibodies combine two different antigen-bind

105 egies predicated on streptavidin and biotin, bispecific antibodies, complementary oligonucleotides, a

106 act specifically with the capture arm of the bispecific antibody complex were used to demonstrate the

107 Use of bispecific antibody complexes and (99m)Tc-DTPA-succinyl-

108 Bispecific antibody complexes and (99m)Tc-labeled negati

109 vel, potently neutralizing, tetravalent, and bispecific antibody composed of 2 heavy-chain-only VH (V

110 nsfer specifically to tumor cells, we used a bispecific antibody conjugate to ablate Ad binding to fi

111 Here we show that bispecific antibodies contain the binding specificities

112 n leukemic cytotoxic T cells triggered via a bispecific antibody containing an anti-CD3 F(ab') to kil

113 l trials have been initiated to test whether bispecific antibodies could redirect immune effectors ag

114 dentical for native diphtheria toxin and the bispecific antibody. CRM107 combination.

115 However, bispecific-antibody design and production remain challen

116 d a DropArray cell-based assay to evaluate a bispecific antibody designed to engage cytotoxic T cells

117 sozyme-specific antibody fragments, creating bispecific antibodies (diabodies).

118 Bispecific antibodies directed against transferrin recep

119 Catumaxomab (CatmAb), a trifunctional bispecific antibody directed against the epithelial cell

120 nded the technology by developing a two-part bispecific antibody discovery strategy that facilitates

121 In contrast, the bispecific antibody does not enhance Ad-GFP infection in

122 This bispecific antibody efficiently induces targeted cell ly

123 All 3 bispecific antibodies exhibited identical pharmacokineti

124 er T (NKT) cells retargeted with a humanized bispecific antibody F(ab')(2)HER2xCD3.

125 tional monoclonal antibodies, knob-into-hole bispecific antibodies face unique challenges in producti

126 experiments revealed that high-affinity TfR bispecific antibodies facilitated the trafficking of TfR

127 To counter this problem, we developed a bispecific antibody (FIT-1) comprising ZKA190 and a seco

128 ath to generating highly effector-attenuated bispecific antibodies for preclinical studies.

129 These findings support the use of bispecific antibodies for the prevention or treatment of

130 h the identification of a common light chain bispecific antibody for large-scale production with high

131 adionuclides, a new anti-Trop-2 x antihapten bispecific antibody for pretargeting, based on humanized

132 While the clinical potential for certain bispecific antibody formats is clear, progress has been

133 en hindered by the difficulty of identifying bispecific antibody formats that exhibit favorable pharm

134 We describe the use of a bispecific antibody fragment (diabody) to recruit the wh

135 The therapeutic potential of bispecific antibody fragments and Fc-containing proteins

136 the construction of other disease-targeting bispecific antibody fragments for early detection and di

137 provides a versatile platform for generating bispecific antibody fragments for redirected killing and

138 Our strategy allows rapid generation of bispecific antibodies from any two existing antibodies a

139 increasing number of multivalent antibodies, bispecific antibodies, fusion proteins, and targeted nan

140 Robust generation of IgG bispecific antibodies has been a long-standing challenge

141 Although human IgG1 bispecific antibodies have been generated, few attempts

142 Bispecific antibodies have been used in different cell s

143 Human bispecific antibodies have great potential for the treat

144 Bispecific antibodies have great potential to be the nex

145 orm conventional monoclonal antibodies, many bispecific antibodies have issues regarding production,

146 Many different formats of bispecific antibodies have meanwhile been developed.

147 Such "Trojan horse" bispecific antibodies have potential as broad antifilovi

148 nerality of the approach and show that these bispecific antibodies have properties similar to those o

149 Bispecific antibodies have therapeutic potential by expa

150 eting" methods, particularly those utilizing bispecific antibodies, have greatly enhanced the therape

151 Bispecific antibodies having binding specificities for t

152 this study, we describe a trastuzumab-based bispecific antibody, HER2-TDB, which targets HER2 and co

153 ti-diethylenetriaminepentaacetic acid (DTPA) bispecific antibody (hMN-14 x m734) (40 mg/m(2)), follow

154 These bispecific antibodies hold promise as novel prophylactic

155 i-CD30 antibodies as well as anti-CD30-based bispecific antibodies, immunotoxins, and radioimmunoconj

156 scaffolds offers the possibility to produce bispecific antibodies in vitro.

157 Comparing high- and low-affinity TfR bispecific antibodies in vivo, we found that high-affini

158 In this study, we characterized bispecific antibodies in which a BBB-crossing antibody f

159 The engineering of bispecific antibodies in which a therapeutic "arm" is co

160 g, this mechanism leads to the production of bispecific antibodies in which the LAIR1 domain is preci

161 Bispecific antibodies, including bispecific IgG, show so

162 We demonstrate here that a bispecific antibody incorporating a broadly reactive ant

163 in advance of the radiolabeled veltuzumab or bispecific antibody injection, tumor uptake was signific

164 T-cell-directed killing of tumor cells using bispecific antibodies is a promising approach for the tr

165 This unique antiangiogenic bispecific antibody is in phase-1 clinical trials.

166 Bispecific antibody is synthesized by covalently linking

167 s of the efficient small-scale generation of bispecific antibodies lacking a common light chain and t

168 , semisynthetic method for the production of bispecific antibody-like therapeutics in which a derivat

169 Using the DEKK format, we generated the bispecific antibody MCLA-128, targeting human EGF recept

170 A bispecific antibody, MDX-H210, was developed to target c

171 totoxic potential, however, was restored via bispecific antibody-mediated delivery and release within

172 Using bispecific antibodies of different valencies to cell sur

173 Emerging bispecific antibodies offer the potential for even bette

174 corporation of FC5 as the BBB-carrier arm in bispecific antibodies or antibody-drug conjugates offers

175 ernative using either (strept)avidin/biotin, bispecific antibodies, or oligomers.

176 We describe the application of a novel, bispecific antibody platform termed dual affinity retarg

177 A BCMA-targeted bispecific antibody presents a promising treatment optio

178 e dramatically improved therapeutic index of bispecific antibody pretargeting appears to be sufficien

179 Bispecific antibody pretargeting has a significant advan

180 Bispecific antibody pretargeting is highly sensitive and

181 Bispecific antibody pretargeting is highly specific for

182 s applied to a peptide suitable for use in a bispecific antibody pretargeting method.

183 ability, enabling efficient knobs-into-holes bispecific antibody production and a robust path to gene

184 Here we present a bispecific-antibody production strategy that relies on c

185 R suggest avenues for the development of new bispecific antibody-promoted treatment strategies.

186 Emicizumab is a bispecific antibody recognizing both the enzyme factor I

187 Bispecific antibodies represent one such strategy in whi

188 This innovative bispecific antibody scaffold that simultaneously engages

189 an affinity-enhancement system consisting of bispecific antibodies separating targeting from delivery

190 Bispecific antibodies show great promise as intrinsic co

191 ing distinct facets of fracture healing, the bispecific antibody shows superior bone repair activity

192 ites, we have focused on the construction of bispecific antibodies specific for the tumor antigen HER

193 Here, we describe a bispecific-antibody strategy to target this interaction,

194 s and yields milligram to gram quantities of bispecific antibodies sufficient for a wide range of dis

195 e have applied this technology to generate a bispecific antibody suitable for development as a human

196 The anti-FcRH5/CD3 T cell-dependent bispecific antibody (TDB) targets the B cell lineage mar

197 port our work expanding the knobs-into-holes bispecific antibody technology to the human IgG4 isotype

198 state cancer using an anti-TROP-2 x anti-HSG bispecific antibody (TF12) in conjunction with the dual-

199 The anti-Trop-2 x antihapten bispecific antibody, TF12, was prepared using the modula

200 onic tumors pretargeted with an anti-CEACAM5 bispecific antibody (TF2).

201 Here, we report engineered bispecific antibodies that are the most potent and broad

202 gammadelta T-cell cytotoxicity, we designed bispecific antibodies that bind CD3 or Vgamma9 on gammad

203 g sites, such as epratuzumab and HU1D10, and bispecific antibodies that can directly interact with ce

204 latform for the mammalian cell production of bispecific antibodies that differ from their parental mA

205 odies that utilize a common light chain, and bispecific antibodies that pair light chains to their co

206 With this approach, we generated potent bispecific antibodies that recruit cytotoxic T lymphocyt

207 Recently, bispecific antibodies that redirect the cytotoxic activi

208 Taken together, our results show how bispecific antibodies that selectively recruit gammadelt

209 antibody constructs including one-armed Abs, bispecific antibodies that utilize a common light chain,

210 As a prototype, we developed a bispecific antibody that binds both vascular endothelial

211 eloid-Specific TNF Inhibitor)--a recombinant bispecific antibody that binds to the F4/80 surface mole

212 the technology with an example of a CD3/CD20 bispecific antibody that effectively depletes B cells in

213 A bispecific antibody that has two different antibody bind

214 rmined whether therapeutic responses using a bispecific antibody that pretargeted (90)Y-hapten-peptid

215 We apply this approach to generate a bispecific antibody that targets IL-4 and IL-13, two cyt

216 For bispecific antibodies, the ratio of the expression level

217 tibodies enables the clinical application of bispecific antibodies to a validated therapeutic pathway

218 ted in the scientific literature that extend bispecific antibodies to other human antibody isotypes.

219 The ability of bispecific antibodies to simultaneously bind two unique

220 racer in situ by pretargeting a multivalent, bispecific antibody to carcinoembryonic antigen (CEA), w

221 Here, we engineered a bispecific antibody to detect K11/K48-linked chains and

222 domain of human tissue factor, by means of a bispecific antibody, to an experimentally induced marker

223 Abs with the potency of cytotoxic agents via bispecific antibody-toxin conjugation.

224 e, we describe a new approach for generating bispecific antibodies using a common light chain format

225 The dual binding capacity of the bispecific antibodies was confirmed by delivery of 125I-

226 As proof-of-concept, a bispecific antibody was employed as an adaptor that phys

227 ons triggered by XGFR, the Fc portion of the bispecific antibody was glycoengineered, which resulted

228 Using the CD70-fiber bispecific antibody, we increased the ability of rAd vec

229 Bispecific antibodies were constructed using genetically

230 Bispecific antibodies were designed to deliver a reversi

231 Approximately 40 microg of bispecific antibodies were injected intravenously after

232 sing T-cell engaging immunotherapies such as bispecific antibodies which target T cells and tumor cel

233 apid generation and chemical optimization of bispecific antibodies, which are termed bispecific CovX-

234 Bispecific antibodies, which simultaneously target CD3 o

235 ology to develop a heterodimeric OAscFab-IgG bispecific antibody, which combines potent signaling inh

236 proach, we synthesized an anti-HER2/anti-CD3 bispecific antibody, which efficiently cross-linked HER2

237 des additional options for the generation of bispecific antibodies with differing effector functions

238 t of patients with malignant gliomas, and of bispecific antibodies with hapten-radionuclides in the t

239 broadens the range of published therapeutic bispecific antibodies with natural surface architecture

240 e efficient heterodimerization, resulting in bispecific antibodies with physiochemical properties ver

241 Labeling of bispecific antibodies with single-photon-emitting isotop

242 itions, resulting in a formation of a stable bispecific antibody with high yields.

243 ases bone mass, we engineer a first-in-class bispecific antibody with single residue pair mutations i

244 We therefore investigated whether a bispecific antibody with specificities for the adenoviru

245 ultaneous targeting of both receptors with a bispecific antibody would lead to enhanced antitumor act

246 The bispecific antibody XGFR is based on the "knob-into-hole

247 owever, most approaches utilized to generate bispecific antibodies yield antibody-like structures tha